These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22681671)

  • 21. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the
    Elkassem AA; Allen BC; Sharbidre KG; Rais-Bahrami S; Smith AD
    AJR Am J Roentgenol; 2021 Sep; 217(3):541-555. PubMed ID: 33759558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?
    Mennitto A; Grassi P; Verzoni E; Ratta R; Procopio G
    J Med Imaging Radiat Oncol; 2017 Apr; 61(2):250-251. PubMed ID: 28070961
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.
    Yin Q; Xu H; Zhong Y; Ni J; Hu S
    BMC Cancer; 2022 Feb; 22(1):163. PubMed ID: 35148700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    Bouchelouche K; Choyke PL
    PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
    Dilhuydy MS; Durieux A; Pariente A; de Clermont H; Pasticier G; Monteil J; Ravaud A
    Oncology; 2006; 70(5):339-44. PubMed ID: 17164590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Positron emission tomography in diagnosis of renal cell carcinoma].
    Bachor R; Kotzerke J; Gottfried HW; Brändle E; Reske SN; Hautmann R
    Urologe A; 1996 Mar; 35(2):146-50. PubMed ID: 8650849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
    Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
    Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
    Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
    Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
    Evangelista L; Basso U; Maruzzo M; Novara G
    Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. F-18 FDG PET in detecting renal cell carcinoma.
    Ak I; Can C
    Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.
    Park S; Lee HY; Lee S
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
    Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
    Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
    García Garzon JR; Bassa P; Llinares E; Soler M; Moragas M; Riera E
    Clin Nucl Med; 2015 Nov; 40(11):910-1. PubMed ID: 26252325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
    Zhu H; Zhao S; Zuo C; Ren F
    AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
    [No Abstract]   [Full Text] [Related]  

  • 36. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
    Ahn T; Roberts MJ; Abduljabar A; Joshi A; Perera M; Rhee H; Wood S; Vela I
    Mol Imaging Biol; 2019 Oct; 21(5):799-807. PubMed ID: 30617728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
    Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
    Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of 18-fluorodeoxyglucose positron emission tomography in the evaluation of tumor cardiac thrombus from renal cell carcinoma.
    García JR; Simo M; Huguet M; Ysamat M; Lomeña F
    Clin Transl Oncol; 2006 Feb; 8(2):124-8. PubMed ID: 16632427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
    Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
    Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.